[com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=1340]]][com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=74457]], camposKey:1029-8428 2022-12-01 Advanced Therapy and Clinical Trials to Treat Patients with Optic Nerve Diseases17391757, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=74458]], camposKey:0914-7470 2022-07-01 Factors influencing mesenchymal stromal cells in in vitro cellular models to study retinal pigment epithelial cell rescue10051015, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=66604]], camposKey:0721-832X 2022-01-01 Acute intraocular toxicity caused by perfluorocarbon liquids: safety control systems of medical devices00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65214]], camposKey:2045-2322 2021-01-12 Intraocular toxicity caused by MEROCTANE perfluorocarbon liquid00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65911]], camposKey:1687-966X 2020-06-27 Mesenchymal Stem Cell Secretome Enhancement by Nicotinamide and Vasoactive Intestinal Peptide: A New Therapeutic Approach for Retinal Degenerative Diseases00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65217]], camposKey:0146-0404 2020-06-01 Is the new ISO 16672.2: 2019 the best prevention to avoid future cases of acute intraocular toxicity by perfluorocarbon liquids?00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=51256]], camposKey:0273-2300 2020-01-01 Chemical compounds causing severe acute toxicity in heavy liquids used for intraocular surgery1045270, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71255]], camposKey:0146-0404 2019-07-01 Mesenchymal stem cells conditioned medium produced on nicotinamide and/or vasoactive intestinal peptide action improve antioxidative/neuroprotective properties in vitro00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=43077]], camposKey:0007-1161 2019-01-01 Acute retinal toxicity associated with a mixture of perfluorooctane and perfluorohexyloctane: Failure of another indirect cytotoxicity analysis4954, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=43073]], camposKey:0146-0404 2019-01-01 Chemical considerations regarding the H-value methodology and its relation with toxicity determination33633364, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53048]], camposKey:0146-0404 2019-01-01 Clinical characteristics of proven acute intraocular toxicity by perfluorocarbon liquids (PFCL) used in retinal surgery00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53049]], camposKey:0146-0404 2019-01-01 Cytotoxicity evaluation of toxic substances identified in recent reported toxic lots of perfluorocarbon liquids used in intraocular surgery in patients00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=49599]], camposKey:0014-4835 2019-01-01 Mesenchymal stem cells provide paracrine neuroprotective resources that delay degeneration of co-cultured organotypic neuroretinal cultures00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71262]], camposKey:0146-0404 2018-07-01 Mesenchymal stem cells reduce neuroretinal degeneration in vitro00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=49606]], camposKey:0721-832X 2018-01-01 Biocompatibility of intravitreal injection of human mesenchymal stem cells in immunocompetent rabbits125134, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11666]], camposKey:2045-2322 2018-01-01 Comparison between direct contact and extract exposure methods for PFO cytotoxicity evaluation00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=49603]], camposKey:0030-3755 2018-01-01 Retinal toxicity of medical devices used during vitreoretinal surgery: A critical overview236243, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52974]], camposKey:0146-0404 2018-01-01 Toxicity of an endotamponade made by a mixture of perfluorooctane and perfluorohexyloctane evaluated by a new cytotoxicity method00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39306]], camposKey:0146-0404 2017-06-01 Acute retinal toxic damage by AlaOcta (R) a liquid perfluorooctane liquid used in retinal detachment surgery. Clinical picture and functional consequences00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71270]], camposKey:0146-0404 2017-06-01 Evaluation of neurotrophic factors secreted by mesenchymal stem cells in co-culture with porcine neuroretinas00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10084]], camposKey:0275-004X 2017-01-01 Acute retinal damage after using a toxic perfluoro-octane for vitreo-retinal surgery11401151, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52640]], camposKey:1755-375X 2017-01-01 Effects of plasma kallikrein inhibitors in an in vitro RPE oxidative stress model00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39307]], camposKey:0146-0404 2017-01-01 Perfluoro-n-octane cytotoxicity in human retinal pigment epithelial cell culture00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39308]], camposKey:0146-0404 2017-01-01 Perfluoro-n-octane cytoxicity in porcine neuroretina organotypic culture00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71272]], camposKey:1043-0342 2016-11-01 Preclinical safety and feasibility of intraocular injection of human mesenchymal stem cells in immunocompetent pigmented-rabbit00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=51252]], camposKey:1090-0535 2016-01-01 A novel coculture model of porcine central neuroretina explants and retinal pigment epithelium cells243253, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52639]], camposKey:1948-0210 2016-01-01 Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials376383, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10049]], camposKey:0030-3755 2016-01-01 Perfluorocarbon Liquids Toxicity: A Sanitary Alert6363, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53483]], camposKey:2605-3535 2016-01-01 Schwann cells culture with adipose stem cells and neuregulin to determine influencing factors applicable in nerve regeneration00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71275]], camposKey:0146-0404 2015-06-01 A NEW METHOD FOR IMPROVING STEM CELLS OBTAINMENT FROM THE PORCINE CILIARY BODY00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71278]], camposKey:0146-0404 2015-06-01 Intravitreal mesenchymal stem cells are safe and well-tolerated in pigmented-rabbit eyes00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71277]], camposKey:0146-0404 2015-06-01 Retinal pigment epithelium cells protect neuroretina from spontaneous degenerative modifications in a porcine co-culture model00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53466]], camposKey:1948-0210 2015-01-01 Current focus of stem cell application in retinal repair641648, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53484]], camposKey:2278-4357 2015-01-01 EVALUATION OF IN VITRO ANTIMICROBIAL ACTIVITY AND
ESSENTIAL OIL COMPOSITION OF ETHANOL EXTRACT OF
VIOLA ODORATA L. LEAVES11211129, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71266]], camposKey:0146-0404 2014-04-01 An organotypic culture model of porcine neuroretina supplemented with porcine retinal pigment epithelium (pRPE) cells to simulate an ex vivo subretinal space00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71268]], camposKey:0146-0404 2014-04-01 Human adipose tissue derived mesenchymal stem cells (hAD-MSCs) together with different combinations of factors delay the degeneration of human neuroretina in indirect co-culture system00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=50771]], camposKey:2211-5420 2014-01-01 Basement membrane promotes ciliary body derived cell spheres formation112118, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=7594]], camposKey:1549-3296 2014-01-01 Bioactive substrates for human retinal pigment epithelial cell growth from elastin-like recombinamers639646, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=49616]], camposKey:2314-6133 2014-01-01 Chitosan feasibility to retain retinal stem cell phenotype and slow proliferation for retinal transplantation00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=6905]], camposKey:0302-766X 2014-01-01 Triple-layered mixed co-culture model of RPE cells with neuroretina for evaluating the neuroprotective effects of adipose-MSCs705716, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=35038]], camposKey:1090-0535 2013-01-01 Adalimumab (tumor necrosis factor-blocker) reduces the expression of glial fibrillary acidic protein immunoreactivity increased by exogenous tumor necrosis factor alpha in an organotypic culture of porcine neuroretina894903, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=13970]], camposKey:0213-3911 2013-01-01 Adipose derived mesenchymal stem cells partially rescue mitomycin C treated ARPE19 cells from death in co-culture condition15771583, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=38600]], camposKey:0022-1759 2013-01-01 Flow cytometry assessment of the purity of human retinal pigment epithelial primary cell cultures6168, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53462]], camposKey:0175-7598 2011-01-01 An exopolysaccharide produced by the novel halophilic bacterium Halomonas stenophila strain B100 selectively induces apoptosis in human T leukaemia cells345355, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=317]], camposKey:1549-3296 2011-01-01 Elastin-like recombinamers as substrates for retinal pigment epithelial cell growth243250, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=54740]], camposKey:1755-375X 2011-01-01 Evaluation of human retinal pigment epithelial cells growth on elastin-like recombinamers substrates00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=38602]], camposKey:0014-4835 2011-01-01 Trypan Blue staining method for quenching the autofluorescence of RPE cells for improving protein expression analysis956962, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52831]], camposKey:1825-0572 2009-01-01 Cell therapies for dry forms of age-related macular degeneration: Therapeutic alternatives are currently in development for atrophic AMD7375, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53463]], camposKey:0882-0139 2008-01-01 UVB-induced murine bone marrow derived macrophages and apoptosis293313, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53464]], camposKey:0969-7128 2005-01-01 Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequences715723][][com.sigma.fs3.argos.domain.gpc.ColabRevistes[id=com.sigma.fs3.argos.domain.gpc.GpcColabRevistesPK[ifcactivitat=COL, ifccomptador=1425]], com.sigma.fs3.argos.domain.gpc.ColabRevistes[id=com.sigma.fs3.argos.domain.gpc.GpcColabRevistesPK[ifcactivitat=COL, ifccomptador=1427]]][][][][][][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=64237]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=62964]]][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=64237]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=62964]]][com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=861]]][com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=861]]][com.sigma.fs3.argos.domain.gpc.GpcTesis[id=com.sigma.fs3.argos.domain.gpc.GpcTesisPK[ifcactivitat=TES, ifccomptador=30474]], com.sigma.fs3.argos.domain.gpc.GpcTesis[id=com.sigma.fs3.argos.domain.gpc.GpcTesisPK[ifcactivitat=TES, ifccomptador=2145636934]]][][][][][][][GpcPartTribunals[ gpcPartTribunalsPK=GpcPartTribunalsPK[ ifcactivitat=PTR, ifccomptador=639 ] ]][][][com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63df0f, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63d4e8, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63ebe5, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63d67b, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e025, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e0f4, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e8c0, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e0c2, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e151, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e1b5, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e12b, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e045, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e171, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e837, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e6b2, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e041, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e869, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e809, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e61a, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e652, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e397, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63d863, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e465, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e9e1][][][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.commons.ArgosPK[act=ESF, cont=61593]]][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.commons.ArgosPK[act=ESF, cont=61593]]][][com.sigma.fs3.argos.domain.gpc.GpcPatents[id=com.sigma.fs3.argos.domain.gpc.GpcPatentsPK[ifcactivitat=PAT, ifccomptador=1460]], com.sigma.fs3.argos.domain.gpc.GpcPatents[id=com.sigma.fs3.argos.domain.gpc.GpcPatentsPK[ifcactivitat=PAT, ifccomptador=1005]]][][com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@465521], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@467c00], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@467c25], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@41316b], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5c29df], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@413bdc]][][][][][][com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@1716a, com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@1734f, com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@155c5][]
